Login to Your Account

CASI kicks off phase II China trials in TNBC, ovarian carcinoma

By Shannon Ellis
Staff Writer

Tuesday, March 31, 2015
SHANGHAI – U.S.-China biotech CASI Pharmaceuticals Inc. initiated dosing in Chinese patients with ENMD-2076, a selective angiogenic kinase inhibitor, in a phase II study for triple-negative breast cancer (TNBC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription